FDA DEVICE FACTS
PD-L1 IHC 22C3 PHARMDX
Agilent Technologies, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
For In vitro diagnostic use.
PD-L1 IHC 22C3 pharmDx is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD -L1 protein in formalin -fixed, paraffin -embedded (FFPE) non- small cell lung cancer (NSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48. PD - L1 protein expression is determined by using Tumor Proportion Score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining. The specimen should be considered PD -L1 positive if TPS ≥ 50% of the viable tumor cells exhibit membrane staining at any intensity.
PD-L1 IHC 22C3 pharmDx is indicated as an aid in ide ntifying NSCLC patients for treatment with KEYTRUDA ® (pembrolizumab).
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。